Assessing possibilities and preventing the risk of using disposables
Posted on April 17, 2013
By: Berthold Bodeker, Chief Scientist
Bayer Pharma AG
Introduction The demand scenario for many individual biopharmaceutical drugs such as monoclonal antibodies (MoAbs) is changing. With the implementation of personalised medicine resulting in drugs for specific, high responder subsets of patients, market volume per drug will decrease. In addition inc...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Related Topics and Keywords
Bayer, bioreactors, chromatography, disposables, extractables and leachables, microfiltration, monoclonal antibody, single-use
Related Product Videos
WAVE Bioreactor™ systems - GE Healthcare Life Sciences
Related Products
MicroCal™ VP-Capillary DSC - GE Healthcare Life SciencesSingle-Use Clipster® Aseptic Disconnector - Sartorius Stedim
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
